A detailed history of Vanguard Group Inc transactions in Minerva Neurosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 252,060 shares of NERV stock, worth $564,614. This represents 0.0% of its overall portfolio holdings.

Number of Shares
252,060
Previous 252,060 -0.0%
Holding current value
$564,614
Previous $804,000 16.29%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$2.5 - $12.47 $117,265 - $584,917
46,906 Added 22.86%
252,060 $650,000
Q2 2023

Aug 14, 2023

BUY
$1.62 - $10.19 $18,169 - $114,291
11,216 Added 5.78%
205,154 $1.88 Million
Q4 2022

Feb 10, 2023

BUY
$1.43 - $13.43 $43,391 - $407,519
30,344 Added 18.55%
193,938 $308,000
Q3 2022

Nov 14, 2022

SELL
$2.53 - $13.17 $831,061 - $4.33 Million
-328,483 Reduced 66.75%
163,594 $1.51 Million
Q2 2022

Aug 12, 2022

BUY
$2.7 - $7.68 $1.33 Million - $3.78 Million
492,077 New
492,077 $1.63 Million

Others Institutions Holding NERV

About Minerva Neurosciences, Inc.


  • Ticker NERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,340,190
  • Market Cap $12M
  • Description
  • Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein ...
More about NERV
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.